Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity.

Liaskou E, Hirschfield GM.

EBioMedicine. 2019 Nov 11. pii: S2352-3964(19)30731-5. doi: 10.1016/j.ebiom.2019.10.056. [Epub ahead of print] No abstract available.

2.

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response.

Murillo Perez CF, Hirschfield GM, Corpechot C, Floreani A, Mayo MJ, van der Meer A, Ponsioen CY, Lammers WJ, Parés A, Invernizzi P, Carbone M, Maria Battezzati P, Nevens F, Kowdley KV, Thorburn D, Mason AL, Trivedi PJ, Lindor KD, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Janssen HLA, Hansen BE, Gulamhusein A; GLOBAL PBC Study Group.

Aliment Pharmacol Ther. 2019 Nov;50(10):1127-1136. doi: 10.1111/apt.15533. Epub 2019 Oct 17.

PMID:
31621931
3.

Comparison of risk scores in the PSC arena.

Goode EC, Hirschfield GM, Rushbrook SM.

Hepatology. 2019 Sep 24. doi: 10.1002/hep.30963. [Epub ahead of print]

PMID:
31550385
4.

The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review.

Lleo A, Leung PSC, Hirschfield GM, Gershwin EM.

Semin Liver Dis. 2019 Sep 19. doi: 10.1055/s-0039-1697617. [Epub ahead of print]

PMID:
31537031
5.

Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines.

Goet JC, Hirschfield GM.

Frontline Gastroenterol. 2019 Jul;10(3):316-319. doi: 10.1136/flgastro-2018-101109. Epub 2019 Jan 9.

PMID:
31281627
6.

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.

Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, Collier J, Dyson JK, Jones DE, Patanwala I, Thain C, Walmsley M, Pereira SP.

Gut. 2019 Aug;68(8):1356-1378. doi: 10.1136/gutjnl-2018-317993. Epub 2019 Jun 1.

7.

A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Onofrio FQ, Hirschfield GM, Gulamhusein AF.

Gastroenterol Hepatol (N Y). 2019 Mar;15(3):145-154.

8.

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.

Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ.

J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11.

PMID:
30980847
9.

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.

Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):445-453. doi: 10.1016/S2468-1253(19)30094-9. Epub 2019 Mar 26.

PMID:
30922873
10.

A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.

Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I, Bacon B, Luketic V, Vuppalanchi R, Medendorp S, Dorenbaum A, Kennedy C, Novak P, Gu J, Apostol G, Hirschfield GM.

Hepatol Commun. 2019 Feb 1;3(3):365-381. doi: 10.1002/hep4.1305. eCollection 2019 Mar.

11.

Liver disease in the young adult: the challenges and rewards.

Thompson FM, Ferguson JW, Kelly DA, Hirschfield GM.

Lancet Gastroenterol Hepatol. 2019 Mar;4(3):248-254. doi: 10.1016/S2468-1253(18)30244-9. Review.

PMID:
30739664
12.

Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus.

Hegade VS, Pechlivanis A, McDonald JAK, Rees D, Corrigan M, Hirschfield GM, Taylor-Robinson SD, Holmes E, Marchesi JR, Kendrick S, Jones DE.

Liver Int. 2019 May;39(5):967-975. doi: 10.1111/liv.14069. Epub 2019 Feb 25.

PMID:
30735608
13.

Autoimmune hepatitis and complexities in management.

Janmohamed A, Hirschfield GM.

Frontline Gastroenterol. 2019 Jan;10(1):77-87. doi: 10.1136/flgastro-2018-101015. Epub 2018 Aug 12. Review.

PMID:
30651962
14.

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HLA, Hansen BE; Global PBC Study Group.

Clin Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028. Epub 2019 Jan 4.

PMID:
30616022
15.

Response to "Is the hub-and-spoke model of care delivery a possible answer to geographical variation in liver transplant outcomes?"

Webb GJ, Hodson J, Chauhan A, O'Grady J, Neuberger JM, Hirschfield GM, Ferguson JW.

Am J Transplant. 2019 Apr;19(4):1248-1249. doi: 10.1111/ajt.15226. Epub 2019 Jan 22. No abstract available.

PMID:
30582276
16.

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.

Goode EC, Clark AB, Mells GF, Srivastava B, Spiess K, Gelson WTH, Trivedi PJ, Lynch KD, Castren E, Vesterhus MN, Karlsen TH, Ji SG, Anderson CA, Thorburn D, Hudson M, Heneghan MA, Aldersley MA, Bathgate A, Sandford RN, Alexander GJ, Chapman RW, Walmsley M; UK-PSC Consortium, Hirschfield GM, Rushbrook SM.

Hepatology. 2019 May;69(5):2120-2135. doi: 10.1002/hep.30479. Epub 2019 Mar 4.

17.

Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom.

Hegade VS, Mells GF, Fisher H, Kendrick S, DiBello J, Gilchrist K, Alexander GJ, Hirschfield GM, Sandford RN, Jones DEJ; UK-PBC Consortium.

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1379-1387.e3. doi: 10.1016/j.cgh.2018.12.007. Epub 2018 Dec 14.

PMID:
30557739
18.

Grand round: Autoimmune hepatitis.

Trivedi PJ, Hubscher SG, Heneghan M, Gleeson D, Hirschfield GM.

J Hepatol. 2019 Apr;70(4):773-784. doi: 10.1016/j.jhep.2018.11.006. Epub 2018 Nov 20. Review.

PMID:
30465775
19.

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U.

J Hepatol. 2019 Mar;70(3):483-493. doi: 10.1016/j.jhep.2018.10.035. Epub 2018 Nov 9.

20.

Pathophysiology of primary biliary cholangitis.

Gulamhusein AF, Hirschfield GM.

Best Pract Res Clin Gastroenterol. 2018 Jun - Aug;34-35:17-25. doi: 10.1016/j.bpg.2018.05.012. Epub 2018 May 24. Review.

PMID:
30343706
21.

Work in Progress: Drugs in Development.

Webb GJ, Hirschfield GM.

Clin Liver Dis. 2018 Aug;22(3):501-515. doi: 10.1016/j.cld.2018.03.004. Epub 2018 May 17. Review.

PMID:
30259849
22.

Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom.

Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA, Jones DEJ; UK-AIH Consortium.

Aliment Pharmacol Ther. 2018 Nov;48(9):951-960. doi: 10.1111/apt.14968. Epub 2018 Sep 18.

23.

Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells.

Liaskou E, Patel SR, Webb G, Bagkou Dimakou D, Akiror S, Krishna M, Mells G, Jones DE, Bowman SJ, Barone F, Fisher BA, Hirschfield GM.

J Autoimmun. 2018 Nov;94:143-155. doi: 10.1016/j.jaut.2018.07.020. Epub 2018 Aug 14.

PMID:
30119881
24.

Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease.

Chung BK, Henriksen EKK, Jørgensen KK, Karlsen TH, Hirschfield GM, Liaskou E.

Hepatol Commun. 2018 Aug 6;2(8):956-967. doi: 10.1002/hep4.1200. eCollection 2018 Aug.

25.

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.

Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF, Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni M, Miele L, Marra F, Giannini E, Gaudio E, Ronca V, Bonato G, Cristoferi L, Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the UK–PBC Consortium.

Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634. doi: 10.1016/S2468-1253(18)30163-8. Epub 2018 Jul 13.

26.

Proximity to transplant center and outcome among liver transplant patients.

Webb GJ, Hodson J, Chauhan A, O'Grady J, Neuberger JM, Hirschfield GM, Ferguson JW.

Am J Transplant. 2019 Jan;19(1):208-220. doi: 10.1111/ajt.15004. Epub 2018 Aug 3.

27.

Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study.

McDonald N, Eddowes PJ, Hodson J, Semple SIK, Davies NP, Kelly CJ, Kin S, Phillips M, Herlihy AH, Kendall TJ, Brown RM, Neil DAH, Hübscher SG, Hirschfield GM, Fallowfield JA.

Sci Rep. 2018 Jun 15;8(1):9189. doi: 10.1038/s41598-018-27560-5.

28.

The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis.

Trivedi PJ, Reece J, Laing RW, Slaney E, Cooney R, Gunson BK, Kamarajah SK, Pinkney T, Thompson F, Muiesan P, Schlegel A, Hirschfield GM, Iqbal T, Ferguson J.

Aliment Pharmacol Ther. 2018 Aug;48(3):322-332. doi: 10.1111/apt.14828. Epub 2018 Jun 8.

PMID:
29882252
29.

Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis.

Jeffery HC, Braitch MK, Bagnall C, Hodson J, Jeffery LE, Wawman RE, Wong LL, Birtwistle J, Bartlett H, Lohse AW, Hirschfield GM, Dyson J, Jones D, Hubscher SG, Klenerman P, Adams DH, Oo YH.

Hepatol Commun. 2018 Feb 26;2(4):421-436. doi: 10.1002/hep4.1163. eCollection 2018 Apr.

30.

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ.

Gut. 2018 Sep;67(9):1568-1594. doi: 10.1136/gutjnl-2017-315259. Epub 2018 Mar 28.

31.

Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.

Webb GJ, Rahman SR, Levy C, Hirschfield GM.

Aliment Pharmacol Ther. 2018 Apr;47(8):1213-1219. doi: 10.1111/apt.14579. Epub 2018 Feb 22.

32.

Quality of life and primary sclerosing cholangitis: The business of defining what counts.

Arndtz K, Hirschfield GM.

Hepatology. 2018 Jul;68(1):16-18. doi: 10.1002/hep.29775. Epub 2018 May 2. No abstract available.

PMID:
29315689
33.

Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.

Eddowes PJ, McDonald N, Davies N, Semple SIK, Kendall TJ, Hodson J, Newsome PN, Flintham RB, Wesolowski R, Blake L, Duarte RV, Kelly CJ, Herlihy AH, Kelly MD, Olliff SP, Hübscher SG, Fallowfield JA, Hirschfield GM.

Aliment Pharmacol Ther. 2018 Mar;47(5):631-644. doi: 10.1111/apt.14469. Epub 2017 Dec 22.

34.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR; Global PBC Study Group.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
35.

Insights into the management of Wilson's disease.

Kathawala M, Hirschfield GM.

Therap Adv Gastroenterol. 2017 Nov;10(11):889-905. doi: 10.1177/1756283X17731520. Epub 2017 Oct 3. Review.

36.

Cellular and Molecular Mechanisms of Autoimmune Hepatitis.

Webb GJ, Hirschfield GM, Krawitt EL, Gershwin ME.

Annu Rev Pathol. 2018 Jan 24;13:247-292. doi: 10.1146/annurev-pathol-020117-043534. Review.

PMID:
29140756
37.

Deciphering the biology of IgG4-related disease: specific antigens and disease?

Haldar D, Hirschfield GM.

Gut. 2018 Apr;67(4):602-605. doi: 10.1136/gutjnl-2017-314861. Epub 2017 Nov 3. No abstract available.

38.

Primary sclerosing cholangitis and the management of uncertainty and complexity.

Arndtz K, Hirschfield GM.

Frontline Gastroenterol. 2017 Oct;8(4):260-266. doi: 10.1136/flgastro-2017-100815. Epub 2017 Jul 25. Review.

39.

Genetic association studies and the risk factors for developing the "Immuno-bile-logic" disease primary biliary cholangitis.

Liaskou E, Hirschfield GM.

Hepatology. 2018 Apr;67(4):1620-1622. doi: 10.1002/hep.29603. Epub 2018 Feb 19. No abstract available.

PMID:
29063616
40.

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.

Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group.

Hepatology. 2018 May;67(5):1890-1902. doi: 10.1002/hep.29569. Epub 2018 Jan 29.

41.

Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.

Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, Vierling JM, Hirschfield GM.

Clin Gastroenterol Hepatol. 2018 Feb;16(2):278-287.e7. doi: 10.1016/j.cgh.2017.09.062. Epub 2017 Oct 6.

PMID:
28993258
42.

Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.

Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HLA, Sherman M, Hirschfield GM, Feld JJ.

J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248-1. doi: 10.1016/j.jhep.2017.07.033. [Epub ahead of print]

PMID:
28844936
43.

Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab.

Mumtaz S, Goh J, Hirschfield GM, Ferguson J, Cooper SC.

Frontline Gastroenterol. 2016 Oct;7(4):271-274. doi: 10.1136/flgastro-2016-100711. Epub 2016 Aug 5.

44.

Autoimmune liver disease: evaluating overlapping and cross-over presentations-a case-based discussion.

Corrigan M, Hirschfield GM.

Frontline Gastroenterol. 2016 Oct;7(4):240-245. doi: 10.1136/flgastro-2016-100698. Epub 2016 Jun 8.

45.

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14.

PMID:
28818518
46.

Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals.

Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin MF, Harper L, Sansom D, Hirschfield GM.

Sci Rep. 2017 Aug 9;7(1):7652. doi: 10.1038/s41598-017-07967-2.

47.

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.

Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrumpf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K; International PSC Study Group, The UK PSC Consortium, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK.

Gut. 2018 Aug;67(8):1517-1524. doi: 10.1136/gutjnl-2016-313598. Epub 2017 Aug 4.

48.

Should we screen for cirrhosis?

Hudson M, Sheron N, Rowe IA, Hirschfield GM.

BMJ. 2017 Jul 12;358:j3233. doi: 10.1136/bmj.j3233. No abstract available.

PMID:
28701337
49.

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

Henriksen EKK, Viken MK, Wittig M, Holm K, Folseraas T, Mucha S, Melum E, Hov JR, Lazaridis KN, Juran BD, Chazouillères O, Färkkilä M, Gotthardt DN, Invernizzi P, Carbone M, Hirschfield GM, Rushbrook SM, Goode E; UK-PSC Consortium, Ponsioen CY, Weersma RK, Eksteen B, Yimam KK, Gordon SC, Goldberg D, Yu L, Bowlus CL, Franke A, Lie BA, Karlsen TH.

HLA. 2017 Oct;90(4):228-233. doi: 10.1111/tan.13076. Epub 2017 Jul 11.

PMID:
28695657
50.

Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.

Trivedi PJ, Scalera I, Slaney E, Laing RW, Gunson B, Hirschfield GM, Schlegel A, Ferguson J, Muiesan P.

J Hepatol. 2017 Nov;67(5):957-965. doi: 10.1016/j.jhep.2017.06.027. Epub 2017 Jul 8.

PMID:
28690174

Supplemental Content

Loading ...
Support Center